KA/EN
Register
Medicines reference
Search
Search
Product

Lasix

Favourites

Furosemide · Sanofi

1 form: tablet. In force in Georgia: 1 of 1 (human register).

Forms and doses1 of 1 in force in Georgia

Form Dose Frequency Georgia
40 mg, Tablet No label dose in the reference yet - Georgia Yes, human
In force until 11 Aug 2027
Human (Ministry of Health, RAMA)
In the register: ლაზიქსი 40 მგ, აბი
№ რ/ა-P-0402
Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration

Lasix 40 mg, Tablet

tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label oral maintenance furosemide for clinically confirmed oedema or volume overload in dogs, especially congestive heart failure, titrated to response and the lowest effective dose
6.8/10
Situational / acceptable
vetman assessment

Lasix

40 mg, tablet, human medicine
Assessed clinical scopeDog · Off-label oral maintenance furosemide for clinically confirmed oedema or volume overload in dogs, especially congestive heart failure, titrated to response and the lowest effective dose · By mouth
Care settingVeterinary-prescribed chronic or step-down oral treatment after diagnosis and stabilisation, with renal, electrolyte, hydration, blood-pressure and congestion monitoring
vetman score 6.8/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ/ა-P-0402 · Verified on 16 Oct 2026 Off-label use

Clinically strong active-ingredient evidence, but the human 40 mg tablet is a coarse veterinary presentation. It is most defensible for an accurately deliverable maintenance dose after stabilisation, with response-guided titration and laboratory monitoring.

Regulatory and scientific credibility6.5/10

The exact 40 mg human product is currently registered in Georgia and another major market. Veterinary 40 mg furosemide tablets are authorised for dogs and cats in the UK and veterinary furosemide tablets are FDA-approved, but neither authorises this exact human brand for veterinary use.

Clinical efficacy8.5/10

Furosemide is a consensus-standard first-line loop diuretic for canine congestive heart failure, with authorised veterinary labels, direct oral PK/diuretic studies and measurements in dogs with CHF. Response and oral bioavailability vary, and evidence for every non-cardiac oedema cause is less direct.

Safety and tolerability6.0/10

The safety profile is well characterised, but excessive or poorly monitored diuresis can cause dehydration, hypotension, azotaemia and sodium, potassium or chloride depletion. Renal function, electrolytes, hydration, blood pressure and concurrent nephrotoxic or ototoxic drugs require active review.

Clinical practicality5.5/10

A validated half-tablet gives a 20 mg step, which can fit some medium or large dogs but is too coarse for many small patients and for fine titration. Published testing shows that split furosemide tablets can vary; smaller doses need a validated lower-strength or compounded formulation.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in anuria, severe hypovolaemia or dehydration, marked electrolyte depletion, or acute glomerular nephritis without resolving the underlying state.
  • Avoid concurrent aminoglycosides where possible and review every nephrotoxic or ototoxic medicine; combined injury risk can outweigh the diuretic benefit.
  • Check renal values and sodium, potassium and chloride before and shortly after initiation or meaningful dose escalation, then at intervals matched to stability.
  • Track hydration, body weight, blood pressure, urine output and resting respiratory rate or other congestion markers; titrate to the lowest effective dose.
  • NSAIDs can blunt diuresis and worsen renal risk; ACE inhibitors, other diuretics and vasodilators can amplify hypotension or azotaemia, while hypokalaemia can increase cardiac-glycoside toxicity.
  • Reduce or reassess promptly with weakness, collapse, poor intake, vomiting, marked thirst, oliguria, rising creatinine or clinically important electrolyte change.
  • This oral tablet is for maintenance or step-down treatment, not a substitute for parenteral stabilisation, oxygen and drainage when acute respiratory distress or a large effusion requires them.
  • Use only the validated half-tablet split. Do not assume quarters provide equal doses; for small patients use a verified lower-strength or compounded formulation.
  • Safety in pregnancy and lactation is not established for these exact products; use only after individual benefit-risk assessment, noting that intense diuresis can reduce lactation.
Assessment sources
  1. Georgia furosemide register2026
  2. VMD furosemide 40 mg SPC2026
  3. FDA furosemide FOI2025
  4. MSD Vet Manual diuretics2026
  5. Furosemide splitting 20212021
  6. ACVIM canine MMVD2019
  7. Dog furosemide PK 20212021
  8. Dog furosemide response 20202020
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label oral maintenance furosemide for clinically confirmed oedema or volume overload in cats, especially congestive heart failure, titrated to response and the lowest effective dose
6.2/10
Situational / acceptable
vetman assessment

Lasix

40 mg, tablet, human medicine
Assessed clinical scopeCat · Off-label oral maintenance furosemide for clinically confirmed oedema or volume overload in cats, especially congestive heart failure, titrated to response and the lowest effective dose · By mouth
Care settingVeterinary-prescribed chronic or step-down oral treatment after diagnosis and stabilisation, with renal, electrolyte, hydration, blood-pressure and congestion monitoring
vetman score 6.2/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ/ა-P-0402 · Verified on 16 Oct 2026 Off-label use

Furosemide has a central feline CHF role, but a 40 mg human tablet is a poor direct fit for feline dosing. Prefer an authorised lower-strength veterinary or validated compounded formulation and monitor renal function and electrolytes closely.

Regulatory and scientific credibility6.5/10

The exact 40 mg human product is currently registered in Georgia and another major market. Veterinary 40 mg furosemide tablets are authorised for dogs and cats in the UK and veterinary furosemide tablets are FDA-approved, but neither authorises this exact human brand for veterinary use.

Clinical efficacy8.0/10

Furosemide is the consensus primary oral diuretic for chronic feline congestive heart failure, supported by authorised veterinary labels and direct feline oral PK data. The consensus evidence level for several feline recommendations is low, absorption is variable and the broad non-cardiac oedema scope is less directly studied.

Safety and tolerability6.0/10

The safety profile is well characterised, but cats with CHF commonly develop azotaemia during treatment and excessive diuresis can cause dehydration, hypotension and electrolyte depletion. Renal function, electrolytes, hydration, blood pressure and concurrent nephrotoxic or ototoxic drugs require active review.

Clinical practicality3.0/10

A typical cat needs a small weight-based dose, while the smallest validated half of this tablet is 20 mg. Informal quartering cannot provide reliable feline titration; use a validated lower-strength veterinary tablet or appropriately compounded liquid instead.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in anuria, severe hypovolaemia or dehydration, marked electrolyte depletion, or acute glomerular nephritis without resolving the underlying state.
  • Avoid concurrent aminoglycosides where possible and review every nephrotoxic or ototoxic medicine; combined injury risk can outweigh the diuretic benefit.
  • Check renal values and sodium, potassium and chloride before and shortly after initiation or meaningful dose escalation, then at intervals matched to stability.
  • Track hydration, body weight, blood pressure, urine output and resting respiratory rate or other congestion markers; titrate to the lowest effective dose.
  • NSAIDs can blunt diuresis and worsen renal risk; ACE inhibitors, other diuretics and vasodilators can amplify hypotension or azotaemia, while hypokalaemia can increase cardiac-glycoside toxicity.
  • Reduce or reassess promptly with weakness, collapse, poor intake, vomiting, marked thirst, oliguria, rising creatinine or clinically important electrolyte change.
  • This oral tablet is for maintenance or step-down treatment, not a substitute for parenteral stabilisation, oxygen and drainage when acute respiratory distress or a large effusion requires them.
  • Use only the validated half-tablet split. Do not assume quarters provide equal doses; for small patients use a verified lower-strength or compounded formulation.
  • Safety in pregnancy and lactation is not established for these exact products; use only after individual benefit-risk assessment, noting that intense diuresis can reduce lactation.
Assessment sources
  1. Georgia furosemide register2026
  2. VMD furosemide 40 mg SPC2026
  3. FDA furosemide FOI2025
  4. MSD Vet Manual diuretics2026
  5. Furosemide splitting 20212021
  6. ACVIM feline cardiomyopathy2020
  7. Cat furosemide PK 20192019
  8. Feline CHF azotemia 20252025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Furosemide40 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Sanofi · France
Registration
Georgia Yes, human
In force until 11 Aug 2027
Human (Ministry of Health, RAMA)
In the register: ლაზიქსი 40 მგ, აბი
№ რ/ა-P-0402
Verified on: 16 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US Discontinued
№ NDA016363, NDA017688
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Active substance doses, with sources

Each dose comes with its source. Check the label of the product you use.

Active substance Furosemide
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
2.5–5 mg/kg Dog, Cat Maintenance By mouth once daily
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Furosoral 10 mg Tablets for Cats and Dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
2 mg/kg Dog Congestive Heart Failure By mouth 2 times daily
ACVIM canine MMVD
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs
Journal of Veterinary Internal Medicine, 2019
1–2 mg/kg Dog, Cat Maintenance Intravenous every 6-8 hours
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Dimazon 50 mg/ml Solution for Injection - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
5 mg/kg Dog, Cat Loading Intravenous once, as the first dose
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Dimazon 50 mg/ml Solution for Injection - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
2 mg/kg
off-label
 Dog Congestive Heart Failure
Emergency
 Intravenous every hour, to a maximum total of 8 mg/kg over 4 hours
ACVIM canine MMVD
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs
Journal of Veterinary Internal Medicine, 2019
0.5–2 mg/kg Cat Congestive Heart Failure By mouth every 8-12 hours
ACVIM feline cardiomyopathy
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats
Journal of Veterinary Internal Medicine, 2020
1–2 mg/kg Cat Congestive Heart Failure
Emergency
 Intravenous as repeated boluses
ACVIM feline cardiomyopathy
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats
Journal of Veterinary Internal Medicine, 2020

Known Contraindications

  • Critical
    Do not use in animals suffering from hypovolaemia, hypotension or dehydration. Do not use in cases of electrolyte deficiency.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in cases of renal failure with anuria. Do not use in acute glomerular nephritis.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in cases of hypersensitivity to furosemide, sulphonamides or to any of the excipients. Furosemide may increase the risk of sulfonamide cross-reactivity.
    Sources: VMD SPC · VMD
  • Warning
    Furosemide should be used with caution in the case of pre-existing electrolyte and/or water imbalance, impaired hepatic function (may precipitate hepatic coma) and diabetes mellitus.
    Sources: VMD SPC · VMD
  • Warning
    Furosemide may alter insulin requirements in diabetic animals.
    Sources: VMD SPC · VMD
  • Warning
    Laboratory studies have shown evidence of teratogenic effects. The safety of the veterinary medicinal product has not been established during pregnancy or lactation.
    Sources: VMD SPC · VMD
  • Warning
    However furosemide is excreted into milk... A deleterious effect on lactation is to be expected, particularly if drinking water is restricted.
    Sources: VMD SPC · VMD

Known Drug Interactions

  • Contraindicated Furosemide + Dihydrostreptomycin
    Do not use concurrently with aminoglycoside antibiotic treatment. In cats, do not use furosemide with ototoxic antibiotics. Concomitant use with aminoglycosides or cephalosporins may increase the risk of nephrotoxicity.
    Recommendation: Do not administer concurrently. If an aminoglycoside is essential, choose a diuretic from another class.
    Sources: VMD SPC · VMD
  • Contraindicated Furosemide + Torasemide
    Do not use concomitantly with other loop diuretics.
    Recommendation: Substitute one for the other rather than adding them. A single torasemide dose is approximately 20 times as potent as a single furosemide dose in the pharmacodynamic model, so milligrams are not directly interchangeable.
    Sources: VMD SPC · VMD
  • Major warning Furosemide + Ceftriaxone
    Concomitant use with aminoglycosides or cephalosporins may increase the risk of nephrotoxicity.
    Recommendation: Monitor renal parameters and hydration. Avoid the combination in a dehydrated patient.
    Sources: VMD SPC · VMD
  • Major warning Furosemide + Prednisolone
    Concurrent use with drugs affecting electrolyte balance (corticosteroids, other diuretics, amphotericin B, cardiac glycosides) requires careful monitoring.
    Recommendation: Monitor electrolytes, particularly potassium. Check periodically during prolonged combination therapy.
    Sources: VMD SPC · VMD
  • Minor warning Furosemide + Amlodipine
    Concomitant use of amlodipine with other agents that may reduce blood pressure may cause hypotension. These agents include: diuretics, beta-blockers, other calcium channel blockers, inhibitors of the renin angiotensin aldosterone system... and alpha-2 agonists. may sometimes result in a decrease in serum potassium and chloride levels
    Recommendation: Before combining amlodipine with these agents, measure blood pressure and ensure that the cat is adequately hydrated. Monitor electrolytes and hydration during treatment.
    Sources: VMD SPC · VMD · IRIS
  • Minor warning Furosemide + Dexamethasone
    The risk of hypokalaemia may be increased if dexamethasone is administered together with potassium depleting diuretics.
    Recommendation: Monitor serum potassium. Hypokalaemia also increases cardiac glycoside toxicity.
    Sources: VMD SPC · VMD
  • Minor warning Robenacoxib + Furosemide
    When robenacoxib is used with drugs that affect renal blood flow, such as diuretics or angiotensin-converting enzyme inhibitors, monitor the patient clinically.
    Recommendation: Monitor the patient clinically and check renal parameters.
  • Minor warning Furosemide + Levothyroxine
    Several drugs, including barbiturates, antacids, anabolic steroids, diazepam, and furosemide, can alter thyroid-hormone binding or metabolism and may affect the response to levothyroxine.
    Recommendation: Recheck T4 and adjust the dose as needed.

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (26 more) Hide additional products

Same active ingredients 7

Same therapeutic group 19

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗